BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261103
DTEND;VALUE=DATE:20261124
DTSTAMP:20260709T125124Z
CREATED:20260709T125124Z
LAST-MODIFIED:20260709T125124Z
UID:43917-1793664000-1795478399@www.pharmajournalist.com
SUMMARY:10th Dermatology Drug Development Summit
DESCRIPTION:10th Dermatology Drug Development Summit – Discovering\, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics – November 3-5\, 2026 | Boston\, MA \nThe 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery\, development\, and commercialization of innovative therapies for inflammatory skin disease. \nMarking a decade of convening the field’s most influential voices\, this year’s summit arrives at a pivotal moment: As competition intensifies across atopic dermatitis and psoriasis\, developers are under growing pressure to demonstrate meaningful differentiation\, accelerate development timelines and identify the next generation of high-value opportunities beyond today’s established targets and therapies. \nDesigned as an intimate\, discussion-led forum\, the summit brings together more than 90 experts spanning discovery\, translational medicine\, preclinical development\, clinical strategy\, medical affairs\, and commercial functions. \nThe meeting provides a unique opportunity to benchmark emerging science\, evaluate novel targets\, and share practical lessons from across the dermatology pipeline. \nAttendees will hear from 40+ senior leaders representing major pharmaceutical companies\, innovative biotechs\, academic research centers\, and patient advocacy organizations\, with representation from AbbVie\, Galderma\, Merck\, SUN Pharma\, Eli Lilly\, UNION Therapeutics and others. \nThis year’s agenda features dual content tracks including Discovery & Preclinical and Clinical & Commercial. \nNew additions include a Pre-Conference Workshop Day\,  offering interactive deep dives into two of dermatology’s fastest-growing areas of innovation: hidradenitis suppurativa\, exploring strategies to drive earlier intervention and disease modification\, and rare & ultra-rare inflammatory skin diseases\, examining how developers can generate meaningful evidence\, overcome translational challenges and unlock scalable opportunities across underserved patient populations. \nWith 10+ hours of in-person networking\, the summit fosters meaningful collaboration among scientists\, clinicians\, executives\, and decisionmakers working to discover\, develop and commercialize the next wave of precision therapeutics. \nFor organizations committed to shaping the future of inflammatory skin disease drug development\, the Dermatology Drug Development Summit remains the essential annual meeting to align on emerging science\, evolving standards of care\, and the path to impactful patient outcomes. \nFind out more about the 10th Anniversary Edition of the Dermatology Drug Development Summit: https://ter.li/rcr0mcj
URL:https://www.pharmajournalist.com/event/10th-dermatology-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261104
DTEND;VALUE=DATE:20261107
DTSTAMP:20260901T132146Z
CREATED:20260901T132146Z
LAST-MODIFIED:20260901T132146Z
UID:44305-1793750400-1794009599@www.pharmajournalist.com
SUMMARY:3rd ADC Payload Summit 2026
DESCRIPTION:3rd ADC Payload Summit | November 4-6\, 2026 | Boston\, USA\nThe 3rd ADC Payload Summit is the premier industry event dedicated exclusively to advancing payload innovation within the antibody-drug conjugate (ADC) landscape. Bringing together leading experts from across payload discovery\, medicinal chemistry\, biology\, translational science\, toxicology\, and ADC development\, the summit provides a focused platform for exploring the next generation of payload technologies and strategies that will shape the future of targeted cancer therapies. \nAs the ADC field continues to expand rapidly\, developers are facing increasing challenges around resistance mechanisms\, safety profiles\, therapeutic index optimization\, and clinical differentiation. This summit is designed to help attendees address these challenges by sharing the latest scientific advances\, practical lessons learned\, and emerging approaches that are driving payload innovation forward. Participants will gain insights into novel payload classes\, dual-payload ADC strategies\, molecular glues\, degrader conjugates\, NMT inhibitors\, and other cutting-edge modalities that have the potential to overcome resistance and improve patient outcomes. \nThe conference agenda features presentations\, panel discussions\, workshops\, and case studies delivered by experts from leading organizations across the ADC ecosystem. Attendees will explore topics including payload selection\, linker-payload design\, clinical translation\, preclinical modeling\, toxicity management\, and the development of differentiated mechanisms of action. The event provides a unique opportunity to benchmark approaches against peers and learn directly from teams developing some of the industry’s most innovative ADC programs. \nIn addition to its scientific content\, the 3rd ADC Payload Summit offers highly interactive networking opportunities designed to foster meaningful collaboration. Through curated matchmaking roundtables\, focused discussion groups\, and dedicated networking sessions\, participants can connect with potential partners\, exchange ideas\, and identify solutions to shared development challenges. \nWhether advancing established payload classes or pioneering entirely new ADC modalities\, attendees will leave the summit with actionable insights\, valuable industry connections\, and a clearer understanding of how to accelerate the development of next-generation ADC therapeutics. \nTo know more visit: https://ter.li/zkq2dnln
URL:https://www.pharmajournalist.com/event/adc-payload-summit-2026/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR